Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

摘要: There have been a large number of studies conducted investigating the use selective serotonin reuptake inhibitors (SSRIs) in treatment patients with premenstrual dysphoric disorder (PMDD). The 12 randomised, controlled trials continuous dose administration SSRIs and eight luteal phase (from ovulation to menses) are reviewed. All on fluoxetine, sertraline, paroxetine citalopram reported positive efficacy. Fluoxetine sertraline largest literature, smaller endorsing citalopram. Mixed efficacy results fluvoxamine. In general, adverse effects from women PMDD usual mild transient including anxiety, dizziness, insomnia, sedation, nausea headache. Sexual dysfunction weight gain can be problematic long-term SSRIs, but these not systematically evaluated SSRI PMDD. Serotonergic antidepressants differential superiority over nonserotonergic Treatments that enhance serotonergic action improve irritability dysphoria rapid onset action, suggesting different mechanism than depression. It is possible neurosteroids, such as progesterone metabolites, involved Future research needs address less frequent regimens, 'symptom-onset' administration, recommended length treatment.